ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, announced today, that it was granted with the Deloitte Technology Fast 50 Award being the leader in life sciences industry. The results were based on the percentage sales growth during the past four financial years (2013-2016). ITM managed to achieve a 174% sales growth in that time interval. The self-developed technology of ITM made a major contribution to company’s success.
Targeted Radionuclide Therapy in Precision Oncology
Targeted Radionuclide Therapy is a medical specialty using very small amounts of radioactive compounds, called radiopharmaceuticals, to diagnose and treat various diseases, like cancer. Targeted radiopharmaceuticals contain a targeting molecule (e.g. peptide or antibody) and a medical radioactive isotope. The technique works by injecting the radio conjugate into the patient’s body where it accumulates in the affected organs or lesions. The targeting molecule binds to a tumor- specific receptor or antigen, according to a lock and key principle and is absorbed by the tumor cells. In most cases the targeting molecule can be used for both diagnosis and therapy – only the radioisotope has to be changed. This opens up the way for the application of Theranostics.
For diagnostic applications radioisotopes with short half-lives are used. With highly sensitive molecular imaging technologies like PET (Positron Emission Tomography) or SPECT (Single Photon Emission Tomography), images of organs and lesions can be created and diseases can therefore be diagnosed in their early stages. Medical radioisotopes with longer half-lives are applied for treatment. The tumor tissue is being destroyed by the radiopharmaceutical emitting cytotoxic doses of ionizing radiation. A highly precise localization of the radioactivity ensures that healthy tissue in the surroundings of the targeted tumor is minimally affected.
Steffen Schuster, CEO of ITM, gave a positive feedback about the sales growth of 174 % during the past financial years. Mr. Schuster said, “This above-average sales growth in recent years displays the sharp rise in demand for our high-quality medical radionuclides. In addition, it also shows that Targeted Radionuclide Therapy is becoming a more promising therapy option for the treatment of cancer. Targeted Radionuclide Therapy has been successfully applied under compassionate use for quite some time already. Furthermore, we are developing our own portfolio of promising product candidates. Our lead candidate Solucin® is currently in the phase III clinical trial COMPETE, which was launched in the spring of 2017. In the foreseeable future, we will approve our first radiopharmaceutical, which would make a significant contribution to treatment outcomes, therefore, improving the quality of life for cancer patients.”
“Companies with impressive innovations that proactively shape digitization have applied this year. We are happy for the courageous entrepreneurs who are successful in the international competition with their own technologies and ideas. Their engagement will be rewarded with the Fast 50 and by this we support the innovation power in German economy”, explained Dr. Andreas Gentner, Partner and Head Technology, Media & Telecommunications EMEA at Deloitte.
- Ends -
About Deloitte
Deloitte provides audit, risk advisory, tax, financial advisory and consulting services to public and private clients spanning multiple industries; legal advisory services in Germany are provided by Deloitte Legal. With a globally connected network of member firms in more than 150 countries, Deloitte brings world-class capabilities and high-quality service to clients, delivering the insights they need to address their most complex business challenges. Deloitte’s approximately 263,900 professionals are committed to making an impact that matters.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. Please see www.deloitte.com/de/UeberUns for a more detailed description of DTTL and its member firms.
About ITM
ITM Isotopen Technologien München AG is a privately held group of companies dedicated to the development, production and global supply of innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals. Since its foundation in 2004, ITM and its subsidiaries have established the GMP manufacturing and a robust global supply network of a novel, first-in-class medical radionuclides and -generator platform for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development addressing a range of cancers such as neuroendocrine cancers or bone metastases. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side-effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.
For more information about ITM, please visit: www.itm.ag
Contact
Nicola Scharrer
Head of Marketing
Phone: +49 89 3298986-16
Mail: Nicola.Scharrer(at)itm.ag
Media Contact: WE Communications
Stephanie Kunz
Account Director
Phone: +49 89 628175-19
Mail: ITM_AG(at)we-worldwide.com
ITM Isotopen Technologien München AGChairman of the Supervisory Board - Udo J. Vetter, Executive Board - Steffen Schuster (Chairman), Thomas DürreRegistered Office of the Company - Lichtenbergstr. 1, 85748 Garching – Commercial Register Munich - HRB 154944
